Distress

20/20 Biolabs (AIDX) files late notice for its first-quarter report

AIDX

20/20 Biolabs, Inc. (Nasdaq: AIDX) said on May 15, 2026 that it could not file its quarterly report for the period ended March 31, 2026 on time. Its 2025 annual report showed cash of $1,025,987.

Investor Chat

Scorecard

AIDX
Investor Impact: 9/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Investment Attractiveness: 5.4/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record

By the aibio.space news desk

Stock prices on an electronic board
Stock prices on an electronic board. CC0, via rawpixel. The picture shows the field, not the companies named.

20/20 Biolabs, Inc. (Nasdaq: AIDX) filed a notice of late filing on May 15, 2026. The company said it could not file its Form 10-Q for the quarter ended March 31, 2026 within the prescribed time, because of unanticipated delays in completing its financial statements. The notice, filed on Form 12b-25, says the company expects to file within five calendar days after the due date.

Why is this important: A late quarterly report is a warning sign for a company already under financial strain. It can prompt questions from Nasdaq, lenders and auditors, and it leaves investors without current numbers. The notice does not say the company will miss the deadline for good, and it gives no reason beyond the delay in its statements. The notice stays open until the report is filed.

Jonathan Cohen, the chief executive, signed the notice and is the contact for the filing. In our view, a company that cannot close its books on time while cash is thin has a control problem that goes beyond one report. The 2025 annual report says the company identified errors in its accounting for stock-based compensation during the preparation of its nine-month financial statements for September 30, 2025, and that it has previously restated its financial statements. The company's annual report for 2025 already said its going concern depends on continued external financing. A delayed quarter shows how little margin the finance function has, and we think the board should explain the cause in plain terms.

What the notice says and what the 2025 report shows

The Form 12b-25 covers the Form 10-Q for the quarter ended March 31, 2026. In Part III the company states that the delays came in completing its financial statements and related parts of the quarterly report, and that they could not be eliminated without unreasonable effort and expense. The company checked the box stating that it would file within five calendar days after the prescribed due date.

The last full set of audited results is in the 2025 annual report, filed on March 31, 2026. It reports cash and cash equivalents of $1,025,987 at December 31, 2025. The net loss for 2025 was $3,738,821, compared with $5,551,667 for 2024. Cash used in operating activities was $1,919,720, which the company attributes mainly to the net loss, partly offset by non-cash charges including $516,180 of stock-based compensation.

The annual report says the company's continuation as a going concern depends on revenue growth that exceeds spending increases, together with continued financial support from external financing. It also says that if the company cannot continue as a going concern, shareholders would likely lose most or all of their investment.

The business behind the numbers

The company develops and sells laboratory-based blood tests for early detection of cancers and chronic diseases. Its lead product is OneTest for Cancer, a multi-cancer early detection test built mainly on protein tumor markers. The annual report says sales of OneTest for Cancer rose to $1,803,707 in 2025 from $323,414 in 2022. The company says its tests are run in a laboratory that is accredited by the College of American Pathologists and licensed under the Clinical Laboratory Improvement Amendments.

The annual report also describes a state funding route for the test. It says several states are creating funds to reimburse fire departments for multi-cancer screening. New Hampshire's program provides $5 million in funding over two years, and Maryland raised its grant program for multi-cancer screening tests to $600,000 for its fiscal year beginning July 2025, from $400,000 the year before. The company expects more states to provide this type of reimbursement over the coming years. The filing does not say how much of the company's sales those programs produced.

The filings describe clinical studies in general terms and cite published work on tumor markers. They do not name a ClinicalTrials.gov study for OneTest for Cancer, and this article cites none.

The next dated item is the filing deadline that follows the notice. The notice says the company expects to file within five calendar days after the prescribed date. Whether that happened is not in the record used for this article.

The notice is filed as the Form 12b-25 filed May 15, 2026. The company's 2025 results, going concern language and business description are in the Form 10-K filed March 31, 2026.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.